Comparative study of intravitreal bevacizumab (avastin) versus ranibizumab (lucentis) in the treatment of neovascular age-related macular degeneration

Ophthalmologica

Volumn 223, Issue 6, 2009, Pages 370-375

  Landa, Gennady ^a,b   Amde, Wendewessen ^a   Doshi, Vatsal ^a,b   Ali, Amro ^a   McGevna, Laura ^c   Gentile, Ronald C ^a,b   Muldoon, Thomas O ^a,b   Walsh, Joseph B ^a,b   Rosen, Richard B ^a,b  

^a NEW YORK EYE AND EAR INFIRMARY   (United States)

^b NEW YORK MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Bevacizumab (Avastin); Choroidal neovascularization; Neovascular age related macular degeneration; Ranibizumab (Lucentis)

Indexed keywords

BEVACIZUMAB; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RANIBIZUMAB;

AGED; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EYE INFLAMMATION; FEMALE; HUMAN; INTRAOCULAR INFLAMMATION; INTRAOCULAR PRESSURE; LEG PAIN; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETINA MACULA AGE RELATED DEGENERATION; SCANNING LASER OPHTHALMOSCOPY; SIDE EFFECT; TREATMENT OUTCOME; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; INJECTIONS, INTRAOCULAR; MACULAR DEGENERATION; MALE; RETINAL NEOVASCULARIZATION; RETROSPECTIVE STUDIES; VISUAL ACUITY; VITREOUS BODY;

EID: 67649884473     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000227783     Document Type: Article

References (19)

1. Buch H, Vinding T, Nielsen NV: Prevalence and causes of visual impairment according to World Health Organization and United States criteria in an aged, urban Scandinavian population: the Copenhagen City Eye Study. Ophthalmology 2001; 108: 2347-2357.
2. Klein R, Klein BEK, Linton KLP: Prevalence of age-related maculopathy: the Beaver Dam Eye Study. Ophthalmology 1992; 99: 933-945.
3. Leibowitz HM, Krueger DE, Maunder LR, et al: The Framingham Eye Study monograph. Surv Ophthalmol 1980; 24: 335-610.
4. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, Kim RY; MARINA Study Group: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
5. Boyer DS, Antoszyk AN, Awh CC, Bhisitkul RB, Shapiro H, Acharya NR; MARINA Study Group: Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114: 246-252. (Pubitemid 46172497)
6. Heier J, Boyer J, Ciulla D, et al: Ranibizumab combined with verteportin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS study. Arch Ophthalmol 2006; 124: 1532-1542.
7. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group: Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145: 862-874.
8. Kaiser PK, Brown DM, Zhang K, Hudson HL, Holz FG, Shapiro H, Schneider S, Acharya NR: Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. Am J Ophthalmol 2007; 144: 850-857.
9. Brown DM, Kaiser PK, Michels M, et al; the ANCHOR Study Group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-1444.
10. Regillo CD, Brown DM, Abraham P, Yue H, Ianchulev T, Schneider S, Shams N: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239-248.
11. Spaide RF, Laud K, Fine HF, Klancnik JM Jr, Meyerle CB, Yannuzzi LA, Sorenson J, Slakter J, Fisher YL, Cooney MJ: Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration. Retina 2006; 26: 383-390. (Pubitemid 44197628)
12. Cleary CA, Jungkim S, Ravikumar K, Kelliher C, Acheson RW, Hickey-Dwyer M: Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results. Eye 2008; 22: 82-86.
13. Aisenbrey S, Ziemssen F, Völker M, Gelisken F, Szurman P, Jaissle G, Grisanti S, Bartz- Schmidt KU: Intravitreal bevacizumab (Avastin) for occult choroidal neovascularization in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 2007; 245: 941-948.
14. Mojica G, Hariprasad SM, Jager RD, Mieler WF: Short-term intraocular pressure trends following intravitreal injections of ranibizumab (Lucentis) for the treatment of wet age-related macular degeneration. Br J Ophthalmol 2008; 92: 584.
15. Fung AE, Rosenfeld PJ, Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Br J Ophthalmol 2006; 90; 1344-1349.
16. Pilli S, Kotsolis A, Spaide RF, Slakter J, Freund KB, Sorenson J, Klancnik J, Cooney M: Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting. Am J Ophthalmol 2008; 145: 879-882.
17. Wu L, Martínez-Castellanos MA, Quiroz- Mercado H, Arevalo JF, Berrocal MH, Farah ME, Maia M, Roca JA, Rodriguez FJ; the Pan American Collaborative Retina Group: Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-87. (Pubitemid 350167096)
18. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT, Emerson GG, Schlesinger TK, Nolte SK, Klein ML: Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27: 439-444.
19. Brown MM, Brown GC, Brown HC, Peet J: A value-based medicine analysis of ranibizumab for the treatment of subfoveal neovascular macular degeneration. Ophthalmology 2007; 115: 1039-1045.